Login / Signup

Switching to aflibercept versus continuing bevacizumab for treatment-resistant neovascular age-related macular degeneration: a one-year comparative observational study.

Yngvil Solheim HusumMorten Carstens MoeRagnheiður BragadóttirØystein Kalsnes Jørstad
Published in: Acta ophthalmologica (2021)
The study suggests that the possibility of switching eyes with treatment-resistant nAMD to aflibercept leads to a modest visual benefit compared with continuing first-line bevacizumab therapy.
Keyphrases
  • age related macular degeneration
  • metastatic colorectal cancer
  • medical education
  • optical coherence tomography
  • bone marrow
  • cell therapy
  • vascular endothelial growth factor